Tempus AI, Inc. announced the clinical launch of the ArteraAI Prostate Test for patients with metastatic hormone-sensitive prostate cancer. The CLIA-certified and CAP-accredited prognostic test represents the first externally developed digital pathology algorithm available through the Tempus platform.

The AI-powered test analyzes patient clinical information and histopathology biopsy images to generate a personalized risk estimate of prostate cancer-specific mortality likelihood. The test targets approximately 25,000 patients newly diagnosed with metastatic prostate cancer in the United States annually.

Clinicians can order the ArteraAI Prostate Test as an add-on to Tempus' solid tumor portfolio across all ordering modalities. The test combines with Tempus' genomic-based next-generation sequencing assay results to provide clinicians with comprehensive patient assessments.

"From the start of our Tempus collaboration, our goal has been to deliver Artera's AI-powered insights to Tempus customers in a streamlined, convenient, and impactful way," said Amanda Lowe, Chief Commercial Officer at Artera.

"By establishing this new digital pathology workflow with the ArteraAI Prostate Test, we are giving clinicians a differentiated tool to better stratify risk and tailor therapy," said Laura Elster, Chief Commercial Officer of Diagnostics at Tempus.

Artera operates as a precision medicine company using multimodal artificial intelligence for cancer care personalization. The company's platform has been validated in multiple Phase 3 randomized trials across different cancers. Artera maintains headquarters in Los Altos, California, and operates a CLIA-certified clinical laboratory in Jacksonville, Florida.

The information is based on a company press release statement.